{"id":528500,"date":"2010-04-15T10:10:10","date_gmt":"2010-04-15T14:10:10","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=73718"},"modified":"2010-04-15T10:10:10","modified_gmt":"2010-04-15T14:10:10","slug":"taligen-adds-maraganore-to-board","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/528500","title":{"rendered":"Taligen Adds Maraganore to Board"},"content":{"rendered":"\n<div style=\"text-transform:uppercase\"><a href=\"http:\/\/www.xconomy.com\/tag\/Biotech\/\">Biotech<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/autoimmune\/\">Autoimmune<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/people\/\">people<\/a><\/div>\n<p>\t\t<strong>Luke Timmerman wrote:<\/strong><\/p>\n<p>Taligen Therapeutics, the Cambridge, MA-based developer of treatments for inflammatory and autoimmune disorders, <a href=\"http:\/\/www.businesswire.com\/portal\/site\/home\/permalink\/?ndmViewId=news_view&amp;newsId=20100415005477&amp;newsLang=en\">said today<\/a> it has added John Maraganore to its board of directors. Maraganore is the CEO of Cambridge, MA-based Alnylam Pharmaceuticals (NASDAQ: <a href=\"http:\/\/finance.yahoo.com\/q?s=ALNY\">ALNY<\/a>) a leader in developing RNA interference treatments. Separately, Taligen said it added two members to its management team: Sven Ante (Bill) Lundberg as chief medical officer, and Karen Tubridy as vice president of clinical operations and regulatory affairs.<\/p>\n<div class=\"postFooter\"><a href=\"http:\/\/www.xconomy.com\/boston\/2010\/04\/15\/taligen-adds-maraganore-to-board\/#comments\">Comments<\/a> | <a href=http:\/\/www.xconomy.com\/reprints\/>Reprints<\/a> | Share: &nbsp;<br \/>\n<a href=\"http:\/\/twitter.com\/home?status=RT%20@Xconomy%20Taligen%20Adds%20Maraganore%20to%20Board%20http:\/\/xconomy.com\/?p=73718\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/twitter.gif\" alt=\"Retweet\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/www.facebook.com\/sharer.php?u=http:\/\/www.xconomy.com\/boston\/2010\/04\/15\/taligen-adds-maraganore-to-board\/&#038;t=Taligen%20Adds%20Maraganore%20to%20Board\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/facebook.gif\" alt=\"Facebook\"\/><\/a><br \/>\n&nbsp;<a href=http:\/\/www.xconomy.com\/boston\/2010\/04\/15\/taligen-adds-maraganore-to-board\/email\/  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/email.gif\" alt=\"Email\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/sharethis.com\/item?publisher=bfda184d-6684-4f7a-a23f-ca4ed4db9287&amp;title=Taligen+Adds+Maraganore+to+Board&amp;url=http%3A%2F%2Fwww.xconomy.com%2Fboston%2F2010%2F04%2F15%2Ftaligen-adds-maraganore-to-board%2F\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/share.gif\" alt=\"Share\"\/><\/a>\n<\/div>\n<p>\t     \t\t<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<a href=\"http:\/\/ads.pheedo.com\/click.phdo?s=0aca5cb1488fdd13e4490ab2275e51bf&#038;p=1\"><img decoding=\"async\" alt=\"\" style=\"border: 0;\" border=\"0\" src=\"http:\/\/ads.pheedo.com\/img.phdo?s=0aca5cb1488fdd13e4490ab2275e51bf&#038;p=1\"\/><\/a><br \/>\n<img loading=\"lazy\" decoding=\"async\" alt=\"\" height=\"0\" width=\"0\" border=\"0\" style=\"display:none\" src=\"http:\/\/ib.adnxs.com\/seg?add=24595&#038;t=2\"\/><\/p>\n<p><a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/rM3cPq8dIzH01R-8IyuIrX85AYY\/0\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/rM3cPq8dIzH01R-8IyuIrX85AYY\/0\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><br \/>\n<a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/rM3cPq8dIzH01R-8IyuIrX85AYY\/1\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/rM3cPq8dIzH01R-8IyuIrX85AYY\/1\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~r\/Xconomy_Full\/~4\/CU136ojDXxY\" height=\"1\" width=\"1\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biotech, Autoimmune, people Luke Timmerman wrote: Taligen Therapeutics, the Cambridge, MA-based developer of treatments for inflammatory and autoimmune disorders, said today it has added John Maraganore to its board of directors. Maraganore is the CEO of Cambridge, MA-based Alnylam Pharmaceuticals (NASDAQ: ALNY) a leader in developing RNA interference treatments. Separately, Taligen said it added two [&hellip;]<\/p>\n","protected":false},"author":1192,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-528500","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/528500","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1192"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=528500"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/528500\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=528500"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=528500"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=528500"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}